sivelestat has been researched along with Critical Illness in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, H; Liu, Y; Luo, M; Sun, Y; Wu, G; Zeng, Z; Zhao, X | 1 |
| Andoh, K; Hoshi, K; Kaise, A; Kato, M; Kurosawa, S; Satoh, D | 1 |
2 other study(ies) available for sivelestat and Critical Illness
| Article | Year |
|---|---|
[Sivelestat sodium for treatment of patients with COVID-19-associated acute respiratory distress syndrome in intensive care unit: a single-center retrospective cohort study].
Topics: C-Reactive Protein; COVID-19; Critical Illness; Humans; Intensive Care Units; Interleukin-6; Pneumonia; Procalcitonin; Retrospective Studies | 2023 |
Sivelestat, a neutrophil elastase inhibitor, reduces mortality rate of critically ill patients.
Topics: Aged; Aged, 80 and over; Critical Illness; Female; Glycine; Hospitals, University; Hospitals, Urban; Humans; Intensive Care Units; Japan; Length of Stay; Leukocyte Elastase; Male; Middle Aged; Multiple Organ Failure; Respiratory Distress Syndrome; Retrospective Studies; Sulfonamides; Treatment Outcome | 2005 |